Based on the BioXcel Therapeutics Inc stock forecast from 1 analysts, the average analyst target price for BioXcel Therapeutics Inc is USD 2.13 over the next 12 months. BioXcel Therapeutics Inc’s average analyst rating is Sell. Stock Target Advisor’s own stock analysis of BioXcel Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, BioXcel Therapeutics Inc’s stock price was USD 1.79. BioXcel Therapeutics Inc’s stock price has changed by -10.05% over the past week, -46.88% over the past month and -95.65% over the last year.
No recent analyst target price found for BioXcel Therapeutics Inc
No recent average analyst rating found for BioXcel Therapeutics Inc
Company Overview BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. Read Less
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs a...Read More
Frequently Asked Questions About BioXcel Therapeutics Inc (BTAI) Stock
Unfortunately we do not have enough data on BTAI's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for BTAI is USD 2.13 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 0.25.
Unfortunately we do not have enough data on BTAI's stock to indicate if its overvalued.
The last closing price of BTAI's stock was USD 1.79.
The most recent market capitalization for BTAI is USD 0.01B.
Based on targets from 1 analysts, the average taret price for BTAI is projected at USD 2.13 over the next 12 months.
This means that BTAI's stock price may go up by +18.72% over the next 12 months.
We can't find any ETFs which contains BioXcel Therapeutics Inc's stock.
As per our most recent records BioXcel Therapeutics Inc has 74 Employees.
BioXcel Therapeutics Inc's registered address is 555 Long Wharf Drive, New Haven, CT, United States, 06511.
You can get more information about it from BioXcel Therapeutics Inc's website at https://www.bioxceltherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About BioXcel Therapeutics Inc (BTAI) Stock
Unfortunately we do not have enough data on BTAI's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for BTAI is USD 2.13 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 0.25.
Unfortunately we do not have enough data on BTAI's stock to indicate if its overvalued.
The last closing price of BTAI's stock was USD 1.79.
The most recent market capitalization for BTAI is USD 0.01B.
Based on targets from 1 analysts, the average taret price for BTAI is projected at USD 2.13 over the next 12 months.
This means that BTAI's stock price may go up by +18.72% over the next 12 months.
We can't find any ETFs which contains BioXcel Therapeutics Inc's stock.
As per our most recent records BioXcel Therapeutics Inc has 74 Employees.
BioXcel Therapeutics Inc's registered address is 555 Long Wharf Drive, New Haven, CT, United States, 06511.
You can get more information about it from BioXcel Therapeutics Inc's website at https://www.bioxceltherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BTAI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
